Sentinext Therapeutics Overview
- Year Founded
-
2008
- Status
-
Out of Business
- Employees
-
11
- Latest Deal Type
-
Out of Business
Sentinext Therapeutics General Information
Description
Developer of safe and efficacious vaccines intended to be used for treating tropical infectious diseases. The company's safe and efficacious vaccines are effective for the treatment of tropical infectious diseases such as EV71, polio, influenza and dengue, enabling healthcare institutions to avail enhanced drugs.
Contact Information
Website
www.sentinext.comCorporate Office
- Suite 19-H, Level 19
- Menara Northam, 55 Jalan Sultan Ahmad Shah
- Penang, 10050
- Malaysia
Corporate Office
- Suite 19-H, Level 19
- Menara Northam, 55 Jalan Sultan Ahmad Shah
- Penang, 10050
- Malaysia
Sentinext Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 5. Out of Business | 01-Apr-2018 | Completed | Out of Business | |||
| 4. Later Stage VC (Series B2) | 25-Jan-2018 | Completed | Generating Revenue | |||
| 3. Early Stage VC (Series B1) | 06-Nov-2014 | Completed | Startup | |||
| 2. Early Stage VC (Series B) | 25-Dec-2011 | $6.34M | $17.9M | Completed | Startup | |
| 1. Early Stage VC (Series A) | 08-Oct-2009 | $11.6M | $11.6M | Completed | Startup |
Sentinext Therapeutics Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series B2 | ||||||||
| Series B1 | ||||||||
| Series B | 6,666,694 | $0.95 | $0.95 | 1x | $0.95 | 21.79% | ||
| Series A | 7,020,199 | $0.89 | $0.89 | 1x | $0.89 | 22.94% |
Sentinext Therapeutics Comparisons
Industry
Financing
Details
Sentinext Therapeutics Competitors (5)
One of Sentinext Therapeutics’s 5 competitors is AB2 Bio, a Venture Capital-Backed company based in Lausanne, Switzerland.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| AB2 Bio | Venture Capital-Backed | Lausanne, Switzerland | ||||
| Sinovac Biotech | Corporation | Beijing, China | ||||
| GeoVax Labs | Corporation | Smyrna, GA | ||||
| Cytodyn | Formerly Angel backed | Vancouver, WA | ||||
| aVaxMed | Venture Capital-Backed | Abingdon, United Kingdom |
Sentinext Therapeutics Signals
Sentinext Therapeutics FAQs
-
When was Sentinext Therapeutics founded?
Sentinext Therapeutics was founded in 2008.
-
Where is Sentinext Therapeutics headquartered?
Sentinext Therapeutics is headquartered in Penang, Malaysia.
-
What is the size of Sentinext Therapeutics?
Sentinext Therapeutics has 11 total employees.
-
What industry is Sentinext Therapeutics in?
Sentinext Therapeutics’s primary industry is Biotechnology.
-
Is Sentinext Therapeutics a private or public company?
Sentinext Therapeutics is a Private company.
-
What is Sentinext Therapeutics’s current revenue?
The current revenue for Sentinext Therapeutics is .
-
How much funding has Sentinext Therapeutics raised over time?
Sentinext Therapeutics has raised $33.5M.
-
Who are Sentinext Therapeutics’s competitors?
AB2 Bio, Sinovac Biotech, GeoVax Labs, Cytodyn, and aVaxMed are competitors of Sentinext Therapeutics.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process